CoChat

Sustained influence of metformin therapy on circulating glucagon‐like peptide‐1 levels in individuals with and without type 2 diabetes

Open access
Preiss, David, Dawed, Adem, Welsh, Paul, Heggie, Alison, Jones, Angus G., Dekker, Jacqueline, Koivula, Robert, Hansen, Tue H., Stewart, Caitlin, Holman, Rury R., Franks, Paul W., Walker, Mark, Pearson, Ewan R., Sattar, Naveed, the DIRECT consortium group · 2017 · Diabetes, Obesity and Metabolism
Cited by 59

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aims: To investigate, in the Carotid Atherosclerosis: Metformin for Insulin Resistance ( CAMERA ) trial ( NCT00723307 ), whether the influence of metformin on the glucagon‐like peptide ( GLP )‐1 axis in individuals with and without type 2 diabetes ( T2DM ) is sustained and related to changes in glycaemia or weight, and to investigate basal and post‐meal GLP ‐1 levels in patients with T2DM in the cross‐sectional Diabetes Research on Patient Stratification ( DIRECT ) study. Materials and methods: CAMERA was a double‐blind randomized placebo‐controlled trial of metformin in 173 participants without diabetes. Using 6‐monthly fasted total GLP ‐1 levels over 18 months, we evaluated metformin's effect on total GLP ‐1 with repeated‐measures analysis and analysis of covariance. In the DIRECT study, we examined active and total fasting and 60‐minute post‐meal GLP ‐1 levels in 775 people recently diagnosed with T2DM treated with metformin or diet, using Student's t‐tests and linear regression. Results: In CAMERA , metformin increased total GLP ‐1 at 6 (+20.7%, 95% confidence interval [ CI ] 4.7‐39.0), 12 (+26.7%, 95% CI 10.3‐45.6) and 18 months (+18.7%, 95% CI 3.8‐35.7), an overall increase of 23.4% (95% CI 11.2‐36.9; P < .0001) vs placebo. Adjustment for changes in glycaemia and adiposity, individually or combined, did not attenuate this effect. In the DIRECT study, metformin was associated with higher fasting active (39.1%, 95% CI 21.3‐56.4) and total GLP ‐1 (14.1%, 95% CI 1.2‐25.9) but not post‐meal incremental GLP ‐1. These changes were independent of potential confounders including age, sex, adiposity and glycated haemoglobin. Conclusions: In people without diabetes, metformin increases total GLP ‐1 in a sustained manner and independently of changes in weight or glycaemia. Metformin‐treated patients with T2DM also have higher fasted GLP ‐1 levels, independently of weight and glycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12826

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 59

Metadata

Authors
Preiss, D., Dawed, A., Welsh, P., Heggie, A., Jones, A. G., Dekker, J., Koivula, R., Hansen, T. H., Stewart, C., Holman, R. R., Franks, P. W., Walker, M., Pearson, E. R., Sattar, N., & the DIRECT consortium group
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-12-28
Volume
19
Issue
3
Pages
356-363
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2549087520
Cited by
59
References
13
FWCI
6.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained influence of metformin therapy on circulating glucagon‐like peptide‐1 levels in individuals with and without type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12826
The paper
Preiss, D., Dawed, A., Welsh, P., Heggie, A., Jones, A. G., Dekker, J., Koivula, R., Hansen, T. H., Stewart, C., Holman, R. R., Franks, P. W., Walker, M., Pearson, E. R., Sattar, N., & the DIRECT consortium group. (2017). Sustained influence of metformin therapy on circulating glucagon‐like peptide‐1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12826

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.